Iofetamine hydrochloride | 82691-32-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Iofetamine hydrochloride
• 英文别名: N-isopropyl-p-iodoamphetamine hydrochloride；hydron;1-(4-iodophenyl)-N-propan-2-ylpropan-2-amine;chloride
• CAS: 82691-32-5
• 化学式: C₁₂H₁₈IN*ClH
• 分子量: 339.647
• InChiKey: AFLDFEASYWNJGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.64
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Iofetamine hydrochloride 以2%的产率得到
  参考文献：
  名称：

  SUN MEIZHEN; HUANG QIANG; LUO MEICHU; LI LANDI; ZHANG MEIZHEN; SHEN BINYU+, NUCL. TECHN., 10,(1987) N 5, 48-51

  摘要：

  DOI：

文献信息

• <i>N</i>-Isopropyl-<i>p</i>-iodoamphetamine Hydrochloride Is Predominantly Metabolized by CYP2C19
  作者：Ken-ichi Fujita、Minako Sugiyama、Yuko Akiyama、Kazuhito Hioki、Munetaka Kunishima、Kodai Nishi、Masato Kobayashi、Keiichi Kawai、Yasutsuna Sasaki

  DOI：10.1124/dmd.111.043893

  日期：2012.5

  [123I] N -Isopropyl- p -iodoamphetamine hydrochloride ([123I]IMP) is clinically used to evaluate blood flow in the brain on single photon emission-computed tomography. This is a rare radiopharmaceutical that undergoes metabolism. The first step is reported to be [123I] p -iodoamphetamine formation. The drug-metabolizing enzyme(s) involved remain(s) unclear. This study examined the roles of human cytochrome P450 (P450) in the metabolism of nonradiolabeled IMP with the use of human liver microsomes (HLM) and recombinant human CYP1A1, -1A2, -1B1, -2A6, -2B6, -2C8, -2C9, -2C19, -2D6, -2E1, -3A4, and -3A5. Disappearance of IMP was examined because p -iodoamphetamine was not available. IMP (0.5 μM) time-dependently disappeared when HLM and NADPH-generating system were added to the reaction mixture. ( S )-Mephenytoin (1 mM) inhibited the IMP disappearance by approximately 90%. The disappearance of IMP was predominantly catalyzed by recombinant CYP2C19, with K m and V max of 8.6 μM and 9.7 nmol · min−1 · nmol P450−1, respectively. IMP disappearance in CYP2C19-deficient HLM ( CYP2C19 * 2 /* 2 ) was approximately 30% of that in the presence of HLM harboring wild-type CYP2C19 , indicating that IMP is polymorphically metabolized by CYP2C19. High-performance liquid chromatography of the incubation mixture of IMP and CYP2C19 revealed an unidentified peak. As the area of the IMP peak decreased, the area of this unidentified peak increased in a time-dependent fashion. The peak was also detectable on incubation of IMP with HLM. Mass spectrometry revealed that the molecular weight of a compound in this unidentified peak was the same as that of p -iodoamphetamine. Thus, we demonstrated that IMP was predominantly metabolized by CYP2C19 to form p -iodoamphetamine.

  that，在用HLM孵育时，质谱显示，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HL�M孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵育时，在用HLM孵
• Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound
  申请人：MALLINCKRODT, INC.(a Missouri corporation)

  公开号：EP0165630A2

  公开（公告）日：1985-12-27

  The invention relates to a method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radio-iodinated aromatic or heteroaromatic compound, in which the (hetero)aromatic nucleus optionally comprises one or more additional substituents, by reacting the corresponding halogenated or diazonium-substituted compound in the presence of a water-soluble acid and of copper ions as a catalyst with a likewise water-soluble chloride, bromide radiobromide, iodide or radio-iodide, in which the reaction is carried out in the presence of one or more reduction agents, which are stable in acid medium, in a quantity exceeding the quantity of catalyst. The invention also relates to a composition suitable for diagnostic examination and to a kit for the preparation thereof. The invention further relates to a method and an equipment for the preparation of said composition.

  本发明涉及一种制备氯化、溴化、放射性溴化、碘化和/或放射性碘化芳香族或杂芳香族化合物的方法，其中（杂）芳香族核可选择地包括一个或多个附加取代基、在水溶性酸和作为催化剂的铜离子存在下，使相应的卤代或重氮代化合物与同样的水溶性氯化物、溴化物、放射性溴化物、碘化物或放射性碘化物反应，其中反应是在一种或多种在酸介质中稳定的还原剂存在下进行的，还原剂的数量超过催化剂的数量。本发明还涉及一种适用于诊断检查的组合物及其制备试剂盒。本发明还涉及制备上述组合物的方法和设备。
• PERFLUORO-T-BUTYL-CONTAINING COMPOUNDS FOR USE IN FLUORINE-19 NMR AND/OR MRI
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：EP0485479B1

  公开（公告）日：1996-04-03
• EP3838246A1
  申请人：——

  公开号：EP3838246A1

  公开（公告）日：2021-06-23
• DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT
  申请人：REGIMEN KIT, INC.

  公开号：US20210205172A1

  公开（公告）日：2021-07-08

  A packaging container for a drug having a recording medium and/or an identification mark for recording and updating one or more arbitrary information(s) selected from the group consisting of the information: an active ingredient of a drug, usage of a drug, drug dose, date of manufacture of a drug, expiration date of a drug, drug shipping date of a drug, traceability of drug delivery route from manufacturing to usage of a drug, and storage conditions (e.g., temperature, light (dark/light), humidity, etc.) including storage temperature and changes thereof, information including the administration date of a drug and a breakdown of the administration, amount of drug presented in drug-enclosing portion.